Navigation Links
Medtronic Device Proves Effective in Parkinson’s Diseas

A recent study has shown that Medtronic Inc.'s (MDT) Activa brain stimulation device, in combination with medication is shown to improve motor functions// as well as quality of life in patients with advanced Parkinson's disease more than in patients receiving only medication.

The study was published in Thursday's issue of the New England Journal of Medicine.

In 2002 the Food and Drug Administration had approved the Activa deep brain stimulation therapy to treat Parkinson's. While earlier studies mainly looked at brain stimulation in treating motor functions, this study looked at quality of life as a main endpoint, in addition to motor functions.

Dr. Richard Kuntz, president of the neurological division of the Minneapolis medical-device company told that the results validate Activa's value by providing additional clinical evidence from this study that was more rigorous than past studies.

This six-month study was conducted on 156 patients below 75 years of age who have had Parkinson's for at least five years and suffer from impaired mobility despite medication. During the study all the patients received medication, and half received neurostimulation treatment with the Activa device.

Patients receiving neurostimulation saw a 25% improvement in quality of life and a 41% improvement in motor functions, compared with virtually no change in patients receiving only medication.

The study reports, "In carefully selected patients, neurostimulation of the subthalamic nucleus is a powerful treatment that alleviates the burden of advanced Parkinson's disease."

The Activa device includes electrodes surgically implanted in the brain and connected by an extension under the skin to a neurostimulator implanted near the collarbone. The electrical stimulation can be noninvasively adjusted.

The study was conducted by German and Austrian researchers. Medtronic has awarded some of the researche rs including lead author Dr. Gunther Deuschl, with compensation and research grants.

Although the German government sponsored the study, Medtronic coordinated investigator meetings and payedfor supplemental insurance for the study's patients.

Dr. C. Warren Olanow, neurology department chairman at New York's Mount Sinai School of Medicine and leader of clinical research that led to Activa's FDA approval for Parkinson's, said the study achieved its endpoints and "further affirms this treatment is effective."

Of the 13 patients who reported severe adverse side effects, 10 received neurostimulation and three received only medication. Of the four deaths, three were in the neurostimulation group and one in the medication-only group.


NLA
'"/>




Related medicine news :

1. Medtronic’s Insulin Pump Receives Regulatory Approva
2. Injection supports Heart Devices
3. New Heart-Screening Device ,An Accurate Predictor Of Heart Disease
4. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
5. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
6. New Implantable Device That Can Keep The Heart Ticking
7. Making MRIs Safe for Patients With Implantable Heart Devices
8. Researchers Develop Device For Detecting Atherosclerotic Plaques
9. A Cheap Device to Stop Snoring from New Zealand
10. Scientists Concerned Over Increasing Malfunction Of Heart Devices
11. Device For Improving Bone Mass In Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial Services, ... preparation services, is providing an update on a charitable event that began earlier ... is a locally recognized nonprofit that provides shelter and care for animals seeking ...
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
Breaking Medicine Technology: